ISRCTN09739757已完成2 期
A randomised, double blind, placebo-controlled study of RAD001 (Everolimus) in the TReatment Of Neurocognitive problems in tuberous sclerosis (TRON)
Cardiff University (UK)0 个研究点目标入组 38 人开始时间: 2011年12月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 38
研究概览
简要总结
2016 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/27515417 protocol 2021 Thesis results in https://orca.cardiff.ac.uk/142676/ (added 14/04/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Definite TSC by current clinical criteria
- •2. Male or female aged 16 to 60 years
- •3. IQ over 60 by Wechsler Abbreviated Scales of Intelligence (WASI) and able to participate in direct neuropsychological tests
- •4. A score falling on, or below, the 5th percentile (approximately equivalent to -1.5 SD) in one or more of the primary outcome measures (updated 24/04/2019. Previously: Deficit of - 2 S.D. or more below normal population mean on a primary outcome measure)
- •5. Calculated glomerular filtration rate (GFR) > 60ml/min/1.73m2
- •6. International Normalized Ratio (INR) 1.5 or less (anticoagulation permitted if target INR on stable dose of warfarin or Low molecular weight (LMW) heparin for > 2 weeks at time of randomisation)
- •7. Adequate liver function as shown by: serum bilirubin less than or equal to 1.5 x upper limit of normal (ULN), alanine aminotranferease (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x ULN
- •8. If sexually active - negative pregnancy test in females at the time of informed consent, contraception for males and pre-menopausal females on study
- •9. Seizure free or stable seizures as defined by no change in type of antiepileptic drugs (AEDs) in 6 months prior to recruitment. Doses of drugs may have been changed in the 6 months prior to recruitment
- •10. Negative Hepatitis B virus (HBV) DNA and Hepatitis C virus (HCV) RNA , polymerase chain reaction (PCR) testing at screening for patients with a positive history of risk factors and/or confirmation of prior HBV/HCV infection
- •11. All patients must be able to communicate well with the investigator, to understand and comply with the requirements of the study, understand and sign the written informed consent
- •12. Female patients of childbearing potential must be prepared to use two acceptable methods of contraception, (e.g. intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening
排除标准
- •1. Prior treatment with an mTOR (mammalian target of rapamycin) inhibitor
- •2. Investigational agent <30 days prior to randomisation
- •3. Surgery in last 2 months
- •4. Previous brain neurosurgery with the exception of SEGA (sub-ependymal giant cell astrocytoma) removal surgery or radiosurgery 5 or more years ago (updated on 24/04/2019. Previously: Previous brain neurosurgery)
- •5. Significant haematological abnormality i.e. haemoglobin < 8g/dL, platelets <80,000/mm3, absolute neutrophil count < 1000/mm3)
- •6. Urine protein/creatinine >0.02g/mmol
- •7. Serum creatinine > 1.5 x ULN
- •8. Uncontrolled hyperlipidaemia (fasting cholesterol > 300mg/dL or >7.75 mmol/L and fasting triglycerides >2.5 x ULN, or diabetes with fasting serum glucose > 1.5 x ULN
- •9. History of myocardial infarction, angina or stroke related to atherosclerosis, or any other significant cardiac disease, human immunodeficiency virus (HIV) seropositivity, organ transplant, malignancy other than squamous or basal cell skin cancer
- •10. Lymphangioleiomyomatosis with forced expiratory volume in 1 second (FEV1) <70% of predicted, or any other restrictive pulmonary disease
- •11. Bleeding diathesis or on oral anti-vitamin K medication other than low dose warfarin
- •12. Pregnancy/lactation
- •13. Live vaccine required during trial
- •14. Use of strong inhibitor or inducer of CYP3AE except for anti epileptic drugs
- •15. Intercurrent infection at time of randomisation
- •16. Inability to complete study materials (outcome measures) in English
- •17. History of significant trauma-related cognitive deficit
- •18. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of Everolimus (e.g. pancreatic insufficiency)
- •19. Known sensitivity to Everolimus or other Rapamycin analogues or to its excipients
- •20. Inability to attend scheduled visits
研究者
相似试验
已完成
2 期
Investigating the effects of dietary nitrate in patients with stable anginaTopic: Cardiovascular diseaseSubtopic: Cardiovascular (all Subtopics)Disease: Cardiovascular PreventionCirculatory SystemCardiovascular disease preventionISRCTN17373946Queen Mary University of London246
已完成
2 期
Fulvestrant and vandetanib in advanced aromatase inhibitor resistant breast cancerCancerMetastatic breast cancerISRCTN13663157Velindre NHS Trust165
已完成
2 期
Innovations in the management of musculoskeletal pain with alpha-lipoic acidFibromyalgiaISRCTN58259979Physicians Services Incorporated Foundation27
已完成
2 期
Repeated application of gene therapy in cystic fibrosis patientsNutritional, Metabolic, EndocrineCystic fibrosisISRCTN71164341Imperial College London (UK)130
已完成
2 期
Collaborative H1N1 Adjuvant Treatment pilot trialCritically ill influenza A/H1N1 infectionInfections and InfestationsInfluenza, virus not identifiedISRCTN45190901St Michael's Hospital (UK)80